In an attempt to catch up with leaders in the red-hot field of cancer immunotherapy, Sanofi and Regeneron have announced a major new research partnership. Sanofi is to make a huge $2.18 billion ...

After more than a decade of working together, Sanofi and Regeneron's drug partnership finally turned a profit recently on the back of strong sales of blockbuster Dupixent. Instead of staying the ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Fueled by Dupixent's $557 million in second-quarter sales, Regeneron on Tuesday reported that its Sanofi antibody partnership posted a $39 million profit, a big turnabout from the same period last ...

Peter Dworkin, a spokesman for Regeneron, said that under terms of their partnership, Sanofi is not allowed to increase its stake beyond 30 percent until five years after the planned 2017 ...

Regeneron Pharmaceuticals Inc. said it plans to cut some staff as it restructures its partnership with French drugmaker Sanofi, with whom it had shared drug sales responsibilities.

Additionally, sanofi-aventis will increase its holdings of Regeneron stock from 4% to 19% with the purchase of 12 million newly issued shares. The company is paying $26 per share, a 51.6% increase ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU) in ...

Regeneron is pushing forward with its investment in cancer immunotherapy, striking a deal with bluebird bio to develop cell therapies. Through its partnership with Sanofi, Regeneron is poised to ...

Regeneron Pharmaceuticals Inc. and Sanofi-Aventis SA said they are expanding their drug development partnership under terms in which the French drug maker will invest more than $1 billion for ...

NEW YORK, Nov 10 (Reuters) - Regeneron Pharmaceuticals Inc and French drugmaker Sanofi-aventis said on Tuesday they have expanded their partnership to develop a number of Regeneron's experimental ...